Intervention Review

You have free access to this content

Rifabutin for treating pulmonary tuberculosis

  1. Geraint R Davies1,*,
  2. Stefania Cerri2,
  3. Luca Richeldi2

Editorial Group: Cochrane Infectious Diseases Group

Published Online: 20 JAN 2010

Assessed as up-to-date: 5 JUL 2007

DOI: 10.1002/14651858.CD005159.pub2

Database Title

Additional Information

How to Cite

Davies GR, Cerri S, Richeldi L. Rifabutin for treating pulmonary tuberculosis. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD005159. DOI: 10.1002/14651858.CD005159.pub2.

Author Information

  1. 1

    University of Liverpool, School of Clinical Sciences, Liverpool, Merseyside, UK

  2. 2

    Policlinico di Modena, Universita di Modena e Reggio Emilia, Divisione di Pneumologia, Modena, Italy

*Geraint R Davies, School of Clinical Sciences, University of Liverpool, Royal Liverpool University Hospital, Prescot Street, Liverpool, Merseyside, L7 8XP, UK. gerrydavies@doctors.org.uk.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 20 JAN 2010

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Summary (59K)Standard (219K)Full (269K)

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Gonzalez 1994 {published data only}
  • Gonzalez-Montaner LJ, Natal S, Yongchaiyud P, Olliaro P. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin. Rifabutin Study Group. Tubercle and Lung Disease 1994;75(5):341-7.
HKCS/BMRC 1992 {published data only}
  • Hong Kong Chest Service/British Medical Research Council. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Hong Kong Chest Service/British Medical Research Council. Tubercle and Lung Disease 1992;73(1):59-67.
McGregor 1996 {published data only}
  • McGregor MM, Olliaro P, Wolmarans L, Mabuza B, Bredell M, Felten MK, et al. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. American Journal of Respiratory and Critical Care Medicine 1996;154(5):1462-7.
Rowinska 1992 {published data only}
  • Rowinska-Zakrzewska E, Slupek A, Graczyk J, Zwolska-Kwiek Z, Augustynowicz-Kopec E, Stambrowska A, et al. Preliminary results of rifabutine (ansamycine LM 427) treatment of patients with newly detected and chronic pulmonary tuberculosis and Mycobacterium infections [Wstepne wyniki leczenia ryfabutyna (ansamycyna LM 427) chorych na nowo wykryta i przewlekla gruzlice pluc oraz na mykobakteriozy]. Pneumologia i Alergologia Polska 1992;60(9-10):81-8.
Schwander 1995 {published data only}
  • Schwander S, Rüsch-Gerdes S, Mateega A, Lutalo T, Tugume S, Kityo C, et al. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. Tubercle and Lung Disease 1995;76(3):210-8.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Burman 2006 {published data only}
  • Burman W, Benator D, Vernon A, Khan A, Jones B, Silva C, et al. Tuberculosis Trials Consortium. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. American Journal of Respiratory and Critical Care Medicine 2006;173(3):350-6.
Chan 1992 {published data only}
  • Chan SL, Yew WW, Ma WK, Girling DJ, Aber VR, Felmingham D, et al. The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis. Tubercle and Lung Disease 1992;73(1):33-8.
Sirgel 1993 {published data only}
  • Sirgel FA, Botha FJ, Parkin DP, Van De Wal BW, Donald PR, Clark PK, et al. The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment. Journal of Antimicrobial Chemotherapy 1993;32(6):867-75.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Burman 2001
Cavusoglu 2004
  • Cavusoglu C, Karaca-Derici Y, Bilgic A. In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Clinical Microbiology and Infection 2004;10(7):662-5.
    Direct Link:
CDC 2000
  • Centers for Disease Control and Prevention. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or non-nucleoside reverse transcriptase inhibitors. Morbidity and Mortality Weekly Reports 2000;49(9):185-9.
Dickinson 1981
  • Dickinson JM, Mitchison DA. Experimental models to explain the high sterilizing activity of rifampicin in the chemotherapy of tuberculosis. American Review of Respiratory Diseases 1981;123(4 Pt 1):367-81.
Dye 1999
  • Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999;282(7):677-86.
Dye 2000
Fox 2001
  • Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. International Journal of Tubercle and Lung Disease 2001;3(10 Suppl 2):231-79.
Gelband 2000
  • Gelband H. Regimens of less than six months for treating tuberculosis. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: ]
Grassi 1996
  • Grassi C, Peona V. Use of rifabutin in the treatment of pulmonary tuberculosis. Clinical Infectious Diseases 1996;22 Suppl 1:50-4.
Heifets 1988
  • Heifets LB, Lindholm-Levy PJ, Iseman MD. Rifabutin: minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis. American Review of Respiratory Diseases 1988;137(3):719-21.
Higgins 2006
  • Higgins J, Green S, editors. Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]; Appendix 5b. www.cochrane.org/resources/handbook/hbook.htm (accessed 1 January 2007).
Ji 1993
  • Ji B, Truffot-Pernot C, Lacroix C. Effectiveness of rifampicin, rifabutin and rifapentine for preventive therapy of mouse tuberculosis in mice. American Review of Respiratory Disease 1993;148(6 Pt 1):1541-6.
Juni 2001
Kunin 1996
  • Kunin CM. Antimicrobial activity of rifabutin. Clinical Infectious Diseases 1996;22 Suppl 1:3-14.
Marsili 1981
  • Marsili L, Pasqualucci CR, Vigeyani A, Gioia B, Schioppacassi G, Oronzo G. New rifamycins modified at positions 3 and 4: synthesis, structure and biological evaluation. Journal of Antibiotics (Tokyo) 1981;34(8):1033-8.
Mitchison 1992
O'Brien 1987
Review Manager 4.2
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003.
Ungheri 1984
  • Ungheri D, Della Bruna C, Sanfilippo A. Activity of the spiropiperidyl rifamycin LM 427 on rifampicin resistant Mycobacterium tuberculosis. Giornale Italiano di Chemioterapia 1984;31(3):211-4.
View Full Article (HTML) Summary (59K)Standard (219K)Full (269K)